PAR 3.77% 25.5¢ paradigm biopharmaceuticals limited..

research reports and media, page-4001

  1. 160 Posts.
    lightbulb Created with Sketch. 42
    I see Romosozumab is causing some issues. Another reason to get exited about PPS entering the market!
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.